Vivos Therapeutics (VVOS) Accumulated Expenses (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Accumulated Expenses data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 120.58% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 120.58% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 498.2% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.6 million, down from $6.0 million in the prior quarter.
• Over the last five years, Accumulated Expenses for VVOS reached as high as $6.0 million in Q4 2025 and fell as low as $724000.0 in Q1 2025.
• Historically, Accumulated Expenses has averaged $1.8 million across 5 years, with a median of $1.5 million in 2023.
• Across the five-year window, Accumulated Expenses slumped 53.14% in 2022 and jumped 498.2% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $1.4 million in 2022, then gained by 10.31% to $1.5 million in 2023, then sank by 33.18% to $1.0 million in 2024, then soared by 498.2% to $6.0 million in 2025, then slumped by 73.33% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.6 million in Q1 2026, $6.0 million in Q4 2025, and $1.2 million in Q3 2025.